Chang-Han Lee

Title: Innovative Contributions of Chang-Han Lee in Antibody Engineering

Introduction

Chang-Han Lee, an accomplished inventor based in Austin, TX, has made significant strides in the field of antibody engineering. With a remarkable portfolio of five patents, he is recognized for his innovative approaches to enhancing the efficacy and longevity of therapeutic antibodies. His work stands out due to its potential applications in improving treatments for various diseases.

Latest Patents

Among Chang-Han Lee's most recent innovations is the patent for "Engineered antibody Fc variants for enhanced serum half-life." This invention comprises mutant or variant Fc domains that show increased binding to FcRn, leading to a longer half-life following administration in vivo. This advancement in antibody design aims to improve the therapeutic outcomes by enhancing the stability and duration of action of antibody-based treatments.

Another key patent involves "Engineered immunoglobulin Fc polypeptides displaying improved complement activation." This patent provides methods and compositions involving polypeptides with aglycosylated antibody Fc domains that feature specific substitutions compared to standard Fc domains. These polypeptides are designed to selectively bind C1q while minimizing binding to the inhibitory FcγRIIb receptor, enabling enhanced complement dependent cytotoxicity (CDC) for targeted therapies.

Career Highlights

Chang-Han Lee's career is marked by a profound commitment to research and development in the biomedical field. He is currently affiliated with the Research Development Foundation, where he actively contributes to groundbreaking research initiatives aimed at tackling pressing health challenges through innovative technological solutions.

Collaborations

Throughout his illustrious career, Chang-Han Lee has collaborated with several distinguished colleagues, including George Georgiou and Tae Hyun Kang. These collaborations foster a dynamic exchange of ideas and research methodologies, enhancing the collective impact of their work in antibody engineering and therapeutic development.

Conclusion

Chang-Han Lee has emerged as a notable figure in the landscape of innovation within antibody research. His inventive contributions, particularly regarding engineered antibody Fc variants and polypeptides, demonstrate his commitment to advancing therapeutic options for patients. With continued collaboration and exploration of novel techniques, Lee’s work promises to enhance the landscape of biopharmaceuticals, potentially leading to improved treatment outcomes for a vast array of diseases.